An oral nanozyme-based composite hydrogel (MXene/CBN@GelMA) is developed for targeted inflammatory bowel disease therapy.
Ma et al. (Thu,) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: